Phase 2 Tuberculosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have evidence of infection with one of these viruses: CMV, EBV, ADV, BKV, or another known virus (confirmed by a lab test), and standard antiviral medicines have not worked or cannot be used.
- Your virus levels in the blood have been rising across two blood tests taken at least 24 hours apart, with a level of 1,000 or more copies per ml of blood.
- Your blood counts have recovered to a basic level: your neutrophils (infection-fighting white blood cells) and platelets are above certain minimum levels (confirm with trial site).
- You have symptoms of a viral disease affecting organs or tissues — such as fever, diarrhea, or swollen lymph nodes — confirmed by lab tests on body fluid or a tissue sample, regardless of blood virus levels.
- You (or your guardian) have signed a written consent form before the trial begins.
- Your kidney and liver are working well enough, based on blood test results being within acceptable ranges (confirm with trial site).
- If the immune cells used in the treatment come from a donor, that donor must be healthy, have normal blood counts, test negative for HIV, hepatitis B, hepatitis C, and tuberculosis, and must not have had chemotherapy, radiotherapy, steroids, or certain antibiotics recently (confirm with trial site).
Who may not be able to join:
- You have tested positive for hepatitis C (HCV), hepatitis B (HBV), HIV, or HTLV.
- You are experiencing moderate to severe graft-versus-host disease (a complication sometimes seen after a transplant), graded at level II to IV (confirm with trial site).
- You have a known intolerance or allergy to albumin (a protein used in the treatment preparation).
- Your doctors expect you to live for less than 4 weeks.
- You have taken part in another experimental cell therapy trial within the past 30 days.
- You have a positive pregnancy test.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lung-Ji Chang, PhD, Shenzhen Geno-Immune Medical Institute
Phone: +86 0755-86573763
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Using CTCAE 4 standard to evaluate the level of adverse events after receiving autologous or allogenic pathogen-specific CTL infusion; Viral load change after Virus-CTL infusion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.